文献速递类风湿关节炎

乌司奴单抗与古塞奇尤单抗治疗活动性类风湿关节炎的随机II期研究

A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate.
PubMed 文献 · Ann Rheum Dis · 2017-01-13

这项随机、安慰剂对照的II期研究纳入甲氨蝶呤(MTX)治疗后仍处于活动期的类风湿关节炎(RA)成人患者,评估皮下注射乌司奴单抗(抗IL-12/23 p40)和古塞奇尤单抗(抗IL-23)的疗效与安全性。第28周时,乌司奴单抗组合并组ACR20应答率53.6%、古塞奇尤单抗组合并组41.3%,与安慰剂组40.0%相比均无统计学显著差异(p=0.101和p=0.877)。两种治疗均未观察到新的安全性信号。

要点

  • 乌司奴单抗和古塞奇尤单抗第28周ACR20应答率与安慰剂相比均无显著差异
  • 截至第48周,各组至少发生一次不良事件的比例相当,感染为最常见不良事件类型
  • 两种抗IL-12/23或抗IL-23治疗未显著改善MTX疗效不佳的活动性RA症状

核心结论

  • 乌司奴单抗或古塞奇尤单抗治疗未显著减轻活动性RA患者的症状和体征。
  • 两种治疗均未观察到新的安全性发现。

研究设计与样本

  • 随机、安慰剂对照的II期研究,患者按1:1:1:1:1随机分配。
  • 安慰剂组n=55,乌司奴单抗90mg每8周组n=55,乌司奴单抗90mg每12周组n=55,古塞奇尤单抗50mg每8周组n=55,古塞奇尤单抗200mg每8周组n=54。
  • 所有患者继续稳定剂量MTX(10-25mg/周),主要终点为第28周ACR20应答比例,安全性监测至第48周。

主要发现

  • 第28周乌司奴单抗组合并组ACR20应答率为53.6%,古塞奇尤单抗组合并组为41.3%,安慰剂组为40.0%。
  • 乌司奴单抗组合并组与安慰剂比较p=0.101,古塞奇尤单抗组合并组与安慰剂比较p=0.877,均无统计学显著差异。
  • 截至第48周,各组至少发生一次不良事件的患者比例相当,感染为最常见不良事件类型。

关键数值与推荐

  • 主要终点为第28周达到ACR20应答的患者比例。
  • MTX剂量维持稳定在10-25mg/周。
  • 乌司奴单抗组合并组与安慰剂比较p=0.101,古塞奇尤单抗组合并组与安慰剂比较p=0.877。

临床怎么用

  • 对于MTX治疗后仍活动且需要生物制剂选择的RA患者,抗IL-12/23 p40或抗IL-23单抗未显示优于安慰剂的疗效。
  • 治疗决策时应优先考虑具有明确RA疗效证据的其他机制药物。

局限性

  • 原文未报告研究局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Interleukin (IL)-12 and IL-23 have been implicated in the pathogenesis of rheumatoid arthritis (RA). The safety and efficacy of ustekinumab, a human monoclonal anti-IL-12/23 p40 antibody, and guselkumab, a human monoclonal anti-IL-23 antibody, were evaluated in adults with active RA despite methotrexate (MTX) therapy. METHODS: Patients were randomly assigned (1:1:1:1:1) to receive placebo at weeks 0, 4 and every 8 weeks (n=55), ustekinumab 90 mg at weeks 0, 4 and every 8 weeks (n=55), ustekinumab 90 mg at weeks 0, 4 and every 12 weeks (n=55), guselkumab 50 mg at weeks 0, 4 and every 8 weeks (n=55), or guselkumab 200 mg at weeks 0, 4 and every 8 weeks (n=54) through week 28; all patients continued a stable dose of MTX (10-25 mg/week). The primary end point was the proportion of patients with at least a 20% improvement in the American College of Rheumatology criteria (ACR 20) at week 28. Safety was monitored through week 48. RESULTS: At week 28, there were no statistically significant differences in the proportions of patients achieving an ACR 20 response between the combined ustekinumab group (53.6%) or the combined guselkumab group (41.3%) compared with placebo (40.0%) (p=0.101 and p=0.877, respectively). Through week 48, the proportions of patients with at least one adverse event (AE) were comparable among the treatment groups. Infections were the most common type of AE. CONCLUSIONS: Treatment with ustekinumab or guselkumab did not significantly reduce the signs and symptoms of RA. No new safety findings were observed with either treatment. TRIAL REGISTRATION NUMBER: NCT01645280.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Smolen JS, Agarwal SK, Ilivanova E, et al. A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate. Ann Rheum Dis. 2017. PMID: 28087506. doi:10.1136/annrheumdis-2016-209831

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。